Setting the research agenda for future clinical trials on the use of biologics in rheumatology.


The introduction of anti-TNF drugs for RA has transformed the outlook for patients and they are now an accepted part of clinical practice [1]. Their use has spread to several other related inflammatory disorders. There are five anti-TNF agents licensed for use in RA in Europe, with even more to come, and several other biologic agents for RA are also… (More)
DOI: 10.1093/rheumatology/keq370


  • Presentations referencing similar topics